|

CD19/CD22-CAR-transduced T cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • B-Cell Leukemia1
  • Leukemia, Lymphocytic, B Cell1
  • B-precursor ALL1
  • B-Non Hodgkin Lymphoma1
  • B-NHL1

Bethesda, Maryland1 trial

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.